Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution
Comparing Epidemiological and Clinical Characteristics of Infantile Hemangioma With Minimal or Arrested Growth (IH-MAG) and Classic Infantile Hemangioma : a Retrospective Study
1 other identifier
observational
224
1 country
1
Brief Summary
Infantile hemangioma (IH) is the most common vascular tumor of infancy, characterized by its clinical history. Absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. Then, after a plateau phase, they slowly involute. However, a subtype of IH named "abortive", "minimal or arrested growth", "reticular" or "telangiectatic" hemangioma differs from typical IH because it doesn't have a proliferative component, or only a minimal one. This subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with "classic" infantile hemangioma. The aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. Also, the investigators aim to compare the clinical characteristics of "classic" infantile hemangiomas and abortive hemangiomas. Lastly, investigators wished to study the evolution of abortive hemangioma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 12, 2021
CompletedStudy Start
First participant enrolled
March 23, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2021
CompletedFirst Posted
Study publicly available on registry
October 18, 2021
CompletedOctober 18, 2021
October 1, 2021
2 months
March 12, 2021
October 4, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of abortive hemangioma among infantile hemangioma
Proportion of abortive hemangioma among infantile hemangioma
baseline
Secondary Outcomes (13)
To compare the epidemiological characteristics between infantile hemangioma and abortive hemangioma : sex
baseline
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : prematurity
baseline
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : birthweight
baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : localization
baseline
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : treatment
baseline
- +8 more secondary outcomes
Study Arms (2)
Infantile hemangioma with minimal or arrested growth
Epidemiological and clinical characteristics of infantile hemangioma with minimal or arrested growth.
Classic infantile hemangioma
Epidemiological and clinical characteristics of classic infantile hemangioma.
Eligibility Criteria
\- Children between 0 and 18 years old followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020 presenting with one or more infantile hemangioma
You may qualify if:
- Children between 0 and 18 years old
- Followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020
- Presenting with one or more infantile hemangioma
You may not qualify if:
- \- Those whoes guardian does not want his data to be collected in this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU de Nancy
Nancy, Grand Est, 54000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
BURSZTEJN Anne-Claire, MD, PhD
Central Hospital, Nancy, France
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 12, 2021
First Posted
October 18, 2021
Study Start
March 23, 2021
Primary Completion
May 30, 2021
Study Completion
August 15, 2021
Last Updated
October 18, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share